Phase 2 Leukaemia Trial, Recruiting NCT07238712 Sponsor: St. Petersburg State Pavlov Medical University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT07238712
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

The eligibility criteria provided appear to contain a formatting error — the inclusion and exclusion criteria listed are identical, which suggests the source document may have a transcription or copy-paste error. The true exclusion criteria cannot be reliably determined from the information provided.

Below is a plain-English summary based only on what is clearly stated, with a note where confirmation is needed.


Who might be able to join this trial:

  • People who have been recommended for a stem cell transplant using a donor (called an allogeneic transplant)
  • People whose available donor is not a perfect 10/10 match across five specific genetic markers (HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1)
  • People whose transplant would use stem cells collected from the blood or from bone marrow
  • People diagnosed with one of the following blood or bone marrow conditions: acute myeloid leukaemia, chronic myeloid leukaemia (Ph+), myelodysplastic syndromes, or myeloproliferative neoplasms
  • People whose disease is considered high-risk, such as having more than 5% abnormal cells remaining after treatment, having certain chromosome changes (such as loss of chromosome 7 or a complex karyotype), having a p53 gene mutation, having treatment-related myelodysplastic syndrome, undergoing a second or later donor transplant after relapse, or having chronic myelomonocytic leukaemia or unclassifiable myeloproliferative neoplasms
  • People who do not have a serious unrelated illness at the time of joining

Who may not be able to join:

  • The exclusion criteria in the source document appear to be identical to the inclusion criteria, which suggests a possible error in the original document (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +78123386265

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
St. Petersburg State Pavlov Medical University
Registry
ClinicalTrials.gov
Start date
10 May 2025
Est. completion
10 December 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Overall survival analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov